MTCR — Metacrine Share News
0.000.00%
Last trade - 00:00HealthcareSpeculativeMicro Cap
U.S. STOCKS ON THE MOVE-Tesla, Phunware, Agenus, Cleveland-Cliffs
Metacrine shares slump after halting one of its NASH programs
Brief: Metacrine Reports Interim Results For Met642 Phase 2A Trial In Patients With NASH
Brief: Metacrine, Inc. Files For Mixed Shelf Of Up To $150 Million - SEC Filing
Brief: Metacrine Achieves Full Enrollment For Met642 Phase 2A Trial In Patients With Nash
Brief: Metacrine Updates Met642 Clinical Development Milestone, Reports Q2 Results
U.S. STOCKS ON THE MOVE-Washington Prime Group, RAPT Therapeutics, Enochian Biosciences
U.S. STOCKS ON THE MOVE-Novavax, Metacrine, Corsair, Entasis
Metacrine jumps as Wainwright starts with 'buy'
Brief: Metacrine Achieves Full Enrollment For Met409 Phase 2A Combination Trial In Patients With Type 2 Diabetes And Nash
Brief: Metacrine Achieves Enrollment Target For MET642 Phase 2A Trial Interim Analysis
Metacrine, Inc. reports results for the quarter ended in March - Earnings Summary
Brief: Metacrine Accelerates MET409 Clinical Development Milestone And Reports First-Quarter 2021 Results
Brief: Metacrine Appoints Julia Owens To Its Board Of Directors
Brief: Metacrine Reports Q4 2020 Financial Results
Brief: Metacrine To Present Final Results From Phase 1 Trial Of MET642
Brief: Metacrine Initiates Phase 2a Trial Of MET642 For Treatment Of Patients With NASH
U.S. STOCKS ON THE MOVE-General Motors, Gilead Sciences, Aclaris, Facebook, ODP
U.S. STOCKS ON THE MOVE-Tesla, Eli Lilly, Boeing, Gilead Sciences, Coherent